Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Aug
25
Today In Oncology
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo